In addition, host immunity plays a critical role in the development of breast cancer, supported by the finding that there is a close correlation between tumour infiltrating lymphocytes (TILs) and a more-favourable prognosis in patients with early-stage triple-negative and HER2-positive breast cancer (8). This evidence concerns the gene ERBB2 and breast carcinoma.